Giuseppe Remuzzi, M.D.
Istituto Di Ricerche Farmacologiche Mario Negri
11
1
1
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
Analytics
Trial Phases
No phase data
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (11)
Showing 10 of 11 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
HS Kim, M.D.
Sinchon severance hospital
Shared therapeutic areas:
SH Park, M.D.
St Vincent's Hospital
Shared therapeutic areas:
Hamid Gourabi, PhD
head of Royan Institute
Shared therapeutic areas:
YJ Lee, M.D.
Korea University
Shared therapeutic areas:
Ali MA Ismail, lecturer
Cairo University
Shared therapeutic areas:
CW Ko, M.D.
Kyungpook National University Hospital
Shared therapeutic areas:
SY Lee, M.D.
SMG-SNU Boramae Medical Center
Shared therapeutic areas:
JY Seo, M.D.
Eulji General Hospital
Shared therapeutic areas:
Jean-Olivier ARNAUD, Director
Assistance Publique Hôpitaux de Marseille
Shared therapeutic areas:
CY Kim, M.D.
daejin medical center
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (11)
Showing 11 of 11 trials
Effect of B-cell Depleting Therapies on PLA2R-specific B Cells in Patients With Membranous Nephropathy
Simulated and Synthetic Health Data: Improving Clinical Research on Rare Diseases. A Real-World Data Simulation of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Trials. A Retrospective, Observational Study
New Advanced Vascular Imaging Ultrasound Protocols
Reproducibility of Multiparametric Renal Magnetic Resonance Imaging on 1.5T MRI Scanners
Artificial Intelligence-based Techniques to Characterize KIdney Microstructure on Histological ImagEs
Artificial Intelligence-based Image Processing Methods to Advance the Characterization of Polycystic Kidney Disease
Mechanisms Underlying SGLT2i Kidney Effect in DKD Progression
Pilot STUDY to Monitor Ex-vivo the Biological Effects of the C3 Inhibitor, PEGCETACOPLAN, on Activation of Complement in Fluid Phase and on Podocytes in Patients With C3G and Primary IC-MPGN
All 11 trials loaded